<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04859920</url>
  </required_header>
  <id_info>
    <org_study_id>MAYNADIE 2020</org_study_id>
    <nct_id>NCT04859920</nct_id>
  </id_info>
  <brief_title>Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region</brief_title>
  <acronym>LymphoVi</acronym>
  <official_title>Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The development of new diagnostic tools and targeted therapy have significantly improved the&#xD;
      management of non-Hodgkin's malignant lymphomas and thus their long-term prognosis. However,&#xD;
      in the study of improved patient management, survival is not the only measurable indicator&#xD;
      and preservation of quality of life is an essential component. In addition, there is little&#xD;
      existing data regarding the determinants of quality of life in patients with diffuse large&#xD;
      B-cell lymphoma (DLBCL) or follicular lymphoma (FL) in the general population in France.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Generic Questionnaire SF-12</measure>
    <time_frame>At inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Specific questionnaire QLQ-C30</measure>
    <time_frame>At inclusion</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">159</enrollment>
  <condition>Diffuse Large Cell Diffuse Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>QLQ-C30, SF-12, HADS, SARASON, EPICES, socio-professional data</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of clinical data and treatments</intervention_name>
    <description>clinical data and treatments</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Diffuse large cell diffuse B lymphoma Follicular Lymphoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with DLBCL or FL between January 1, 2010 and December 31, 2017,&#xD;
&#xD;
          -  Alive as of January 1, 2021,&#xD;
&#xD;
          -  Updated patient address.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other forms of Hematologic Malignancies at diagnosis,&#xD;
&#xD;
          -  Minors.&#xD;
&#xD;
          -  Person subject to legal protection (curatorship, guardianship)&#xD;
&#xD;
          -  Person subject to a judicial safeguard measure&#xD;
&#xD;
          -  Pregnant, parturient or breastfeeding woman&#xD;
&#xD;
          -  Adults incapable of giving consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Marc Maynadié</last_name>
    <phone>03 80 39 34 16</phone>
    <email>marc.maynadie@u-bourgogne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Dijon Bourogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc Maynadié</last_name>
      <phone>03 80 39 34 16</phone>
      <email>marc.maynadie@u-bourgogne.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

